Kiniksa Pharmaceuticals (Nasdaq:KNSA) announced today that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase up to 1,200,000 additional Class A common shares. All of the Class A common shares are being offered by Kiniksa. As quoted in the …

As quoted in the press release:

Concurrent with the public offering, Kiniksa intends to sell, subject to the consummation of the public offering and other customary conditions, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), 2,000,000 Class A1 common shares to one or more existing shareholders affiliated with certain of Kiniksa’s directors at a sale price equal to the price to the public in the public offering. However, the consummation of the public offering is not contingent on the consummation of this concurrent private placement.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Barclays Capital Inc. are acting as joint book-running managers for the public offering. Wedbush Securities Inc. and JMP Securities LLC are acting as co-managers for the public offering.

Click here to read the full press release.